Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

Novel Malaria drug KAE 609 Phase II results published in NEJM- Novartis

01-Aug-2014

Novartis has published clinical ...

FDA approves Eylea for treatment of Diabetic Macular Edema- Regeneron

01-Aug-2014

Regeneron Pharmaceuticals, Inc. has ...

Arzerra trial for CLL meets endpoint in interim analysis-GSK/Genmab

01-Aug-2014

GlaxoSmithKline and Genmab have ...

Phase I trial of PD 01A vaccine for Parkinsons meets primary endpoint-AFFiRiS

01-Aug-2014

AFFiRiS AG has presented data from a ...

FDA committee supports HyQ via for Primary Immune Deficiency-Baxter

01-Aug-2014

The Blood Products Advisory Committee ...

Alirocumab success in ODYSSEY trials for Hypercholesterolemia- Sanofi + Regeneron.

31-Jul-2014

Sanofi and Regeneron Pharmaceuticals, ...

Phase III data on Belviq published in Obesity-Eisai/Arena Pharma

31-Jul-2014

Eisai and Arena Pharmaceuticals have ...

Recent Updates

Drugs

Clinical Guidelines

Bacterial Sepsis following Pregnancy

Initial assessment and referral following emergency treatment for an anaphylactic episode

EFNS guideline on the management of status epilepticus in adults

Diagnosis and management of chronic graft-versus-host disease

Medical Journals

The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer

Green tea supplementation increases glutathione and plasma antioxidant capacity in adults with the metabolic syndrome

Is linezolid a risk factor for Gram-negative bacillus infections in intensive care unit patients? A comparative study with vancomycin

Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial

epgonline.org Social